PDCD1 and melanoma: In contrast, a retrospective study involving 749 patients with melanoma who received Abs compared to 1856 non-exposed patients suggested that Abs use prior to anti-PD-1 treatment was not linked to poorer outcomes, either in terms of OS or time to treatment discontinuation [62].